These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30907010)

  • 21. [Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].
    Cazenave JP
    Transfus Clin Biol; 2011 Apr; 18(2):53-61. PubMed ID: 21474358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet transfusion practice and related transfusion reactions in a large teaching hospital.
    Liker M; Bojanić I; Plenković F; Lukić M; Tomac G; Raos M; Golubić Ćepulić B
    Transfus Clin Biol; 2022 Feb; 29(1):37-43. PubMed ID: 34411746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.
    Eriksson L; Kristensen J; Olsson K; Bring J; Högman CF
    Vox Sang; 1996; 70(2):69-75. PubMed ID: 8801766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of the time of storage and transfusion reactions to platelet concentrates from buffy coats.
    Riccardi D; Raspollini E; Rebulla P; Pappalettera M; Marangoni F; Greppi N; Sirchia G
    Transfusion; 1997 May; 37(5):528-30. PubMed ID: 9149780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects.
    Rosskopf K; Helmberg W; Schlenke P
    Transfusion; 2020 Sep; 60(9):2058-2066. PubMed ID: 32619068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage.
    Cancelas JA; Genthe JR; Stolla M; Rugg N; Bailey SL; Nestheide S; Shaz B; Mack S; Schroeder K; Anani W; Szczepiorkowski ZM; Dumont LJ; Yegneswaran S; Corash L; Mufti N; Benjamin RJ; Erickson AC
    Transfusion; 2022 Aug; 62(8):1619-1629. PubMed ID: 35808974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysregulated pathways and differentially expressed proteins associated with adverse transfusion reactions in different types of platelet components.
    Aloui C; Barlier C; Awounou D; Thiam S; Fagan J; Claverol S; Tavernier E; Mounier C; Hamzeh-Cognasse H; Cognasse F; Garraud O; Laradi S
    J Proteomics; 2020 Apr; 218():103717. PubMed ID: 32088354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transfusion-Transmitted Infections Reported to the National Healthcare Safety Network Hemovigilance Module.
    Haass KA; Sapiano MRP; Savinkina A; Kuehnert MJ; Basavaraju SV
    Transfus Med Rev; 2019 Apr; 33(2):84-91. PubMed ID: 30930009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Febrile reactions to platelet transfusion: the effect of increased interleukin 6 levels in concentrates prepared by the platelet-rich plasma method.
    Muylle L; Wouters E; Peetermans ME
    Transfusion; 1996 Oct; 36(10):886-90. PubMed ID: 8863775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transfusion of pathogen-reduced platelet components without leukoreduction.
    Sim J; Tsoi WC; Lee CK; Leung R; Lam CCK; Koontz C; Liu AY; Huang N; Benjamin RJ; Vermeij HJ; Stassinopoulos A; Corash L; Lie AKW
    Transfusion; 2019 Jun; 59(6):1953-1961. PubMed ID: 30919465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of storage of platelet concentrates in PAS-B, PAS-C, or plasma on transfusion reactions.
    van Hout FMA; Middelburg RA; van der Meer PF; Pors A; Wiersum-Osselton JC; Schipperus MR; Kerkhoffs JL; van der Bom JG
    Transfusion; 2019 Oct; 59(10):3140-3145. PubMed ID: 31503334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of random versus apheresis platelet concentrates.
    Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
    Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of hypotension and acute hypotensive transfusion reactions following platelet concentrate transfusions.
    Du Pont-Thibodeau G; Robitaille N; Gauvin F; Thibault L; Rivard GÉ; Lacroix J; Tucci M
    Vox Sang; 2016 Feb; 110(2):150-8. PubMed ID: 26389829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
    Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
    Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic activity of RANTES in apheresis PLT concentrates and its involvement in nonhemolytic transfusion reactions.
    Wakamoto S; Fujihara M; Kuzuma K; Sato S; Kato T; Naohara T; Kasai M; Sawada K; Kobayashi R; Kudoh T; Ikebuchi K; Azuma H; Ikeda H
    Transfusion; 2003 Aug; 43(8):1038-46. PubMed ID: 12869108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events.
    Hamzeh-Cognasse H; Laradi S; Osselaer JC; Cognasse F; Garraud O
    Vox Sang; 2015 Feb; 108(2):205-7. PubMed ID: 25334045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transfusion-related adverse reactions: Data from the National Healthcare Safety Network Hemovigilance Module - United States, 2013-2018.
    Kracalik I; Mowla S; Basavaraju SV; Sapiano MRP
    Transfusion; 2021 May; 61(5):1424-1434. PubMed ID: 33880771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency and clinical characteristics of allergic transfusion reactions in children.
    Kulhas Celik I; Koca Yozgat A; Dibek Misirlioglu E; Ok Bozkaya İ; Civelek E; Toyran M; Yarali N; Ozbek NY
    Transfus Apher Sci; 2021 Aug; 60(4):103152. PubMed ID: 33947611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.
    Lanteri MC; Santa-Maria F; Laughhunn A; Girard YA; Picard-Maureau M; Payrat JM; Irsch J; Stassinopoulos A; Bringmann P
    Transfusion; 2020 Jun; 60(6):1319-1331. PubMed ID: 32333396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of transfusion-related adverse reactions per patient reflects the potential risk of transfusion therapy in Japan.
    Kato H; Uruma M; Okuyama Y; Fujita H; Handa M; Tomiyama Y; Shimodaira S; Kurata Y; Takamoto S
    Am J Clin Pathol; 2013 Aug; 140(2):219-24. PubMed ID: 23897258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.